Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Theravance’s Revefenacin On Track For 2017 Filing With Success In Two Pivotal Trials

Executive Summary

Partnered with Mylan to bring the first once-daily nebulized LAMA bronchodilator to market for COPD, Theravance reports statistical significant in two Phase III studies and now awaits data expected next year from an open-label safety study.

You may also be interested in...



Keeping Track: A Little Bit Of (Nearly) Everything

The latest drug development news and highlights from our US FDA Performance Tracker.

Mylan's Cold-Eeze OTC Acquisition Aims To Leverage Respiratory Expertise

Mylan could tap respiratory product experience to develop line extensions to the homeopathic product, now seen as the centerpiece of its US consumer business.

Mylan, Theravance to partner on nebulized COPD drug

Mylan will spend $45m up front and pay up to $220m in milestone fees plus royalties to co-develop TD-4208, Theravance Biopharma's once-daily long-acting muscarinic antagonist (LAMA) delivered by a nebulizer for chronic obstructive pulmonary disease (COPD) and other respiratory diseases.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

LL1133990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel